ChemDiv Continues R&D Services Support for Clywedog Therapeutics Following Merger with Barinthus Therapeutics

Core Insights - ChemDiv will continue to provide support to Clywedog Therapeutics as it merges with Barinthus Therapeutics, forming a new entity named Clywedog Therapeutics, Inc. The merger aims to advance clinical-stage candidates in Type 1 diabetes, Type 2 diabetes, and celiac disease [1][4]. Company Overview - ChemDiv is a global provider of integrated drug discovery solutions, offering a comprehensive range of services including medicinal chemistry, computational modeling, and clinical pharmacology support [7]. - Clywedog Therapeutics focuses on metabolic and autoimmune diseases, with key programs targeting Type 1 and Type 2 diabetes [6]. - Barinthus Biotherapeutics specializes in developing immunotherapeutics for autoimmune and inflammatory diseases, having rebranded from Vaccitech plc in 2023 [5]. Merger Details - The merger between Barinthus and Clywedog is expected to close in the first half of 2026, combining expertise in immunology and metabolic disease with three clinical-stage assets and multiple near-term data milestones [4]. - The new company will operate under the ticker CLYD on Nasdaq upon closing [1]. Collaborative Efforts - ChemDiv's collaboration with Clywedog includes accelerated CMC research, AI-enabled pharmacology, and translational biology, facilitating the transition of Clywedog's programs to clinical stages in 2023-2024 [2]. - The partnership has successfully advanced MENÂ PPI inhibitors and TYK2 inhibitors, which show promise in treating Type 2 and Type 1 diabetes, respectively [3].